B
bioAffinity Technologies D
D
BIAF
2.83000
USD
0.03
(1.07%)
Market Closed
Volume
13,509
EPS
0
Div Yield
-
P/E
-0
Market Cap
12,731,250
Title: bioAffinity Technologies Inc
Sector: Healthcare
Industry: Diagnostics & Research
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flowcytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.